ArticleAAPS PharmSciTech2026
Nanocrystallization and Microencapsulation of Natural Pigments for Improved Dissolution and Stability.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoparticle-Mediated Lutein Delivery for Diabetic Retinopathy: From Blood-Retinal Barrier Crossing to Neurovascular Unit Protection.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural lipophilic pigments typically exhibit poor water solubility, low dissolution rates, and photothermal instability, which hinder their pharmaceutical application. To address these challenges, a nanosuspension-microencapsulation delivery system was developed using curcumin (CUR) and lutein (LUT) as model compounds to enhance dissolution and stability. Hydroxypropyl methylcellulose E5 (HPMC-E5) was identified as the optimal stabilizer for CUR and LUT nanosuspensions (NS) prepared by antisolvent precipitation and optimized by wet media milling. The resulting CUR-NS achieved a rapid dissolution of 93.29 ± 3.43% within 5 min compared with 26.71 ± 1.11% for raw CUR, while LUT-NS reached 85.13 ± 2.27% at 120 min versus 13.35 ± 1.32% for raw LUT. To enhance powder properties and stability, nanosuspensions were transformed into microcapsules via spray drying and bottom-spray fluidized bed coating, yielding drug loadings of 10-30%. The spray-dried CUR microcapsules exhibited poor flowability (angle of repose: 47°), which improved to 33° after surface modification with 3% colloidal silica. In contrast, CUR and LUT microcapsules prepared with sucrose-based cores via fluidized bed coating showed larger particle sizes, smoother surfaces, excellent flowability (angle of repose ~ 20°), and direct compression suitability. Accelerated stability tests revealed 1.3- to fourfold improvements in resistance to heat, light, and humidity compared with the raw pigments. Furthermore, compressibility evaluations confirmed good tableting performance for all microcapsules. Overall, this study demonstrates a robust nanosuspension-microencapsulation strategy that markedly enhances the dissolution, stability, and processing performance of poorly soluble natural pigments, highlighting its promise for industrial formulation and application.
Indexed as
Identifiers
41612006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.